NASDAQ: NIKINiki Biosolutions Inc Stock
$7.00+0.08 (+1.16%)
Updated Jul 17, 2026
NIKI Price
$7.00
Fair Value Price
$0.00
Market Cap
$57.01M
52 Week Low
$6.00
52 Week High
$44.70
P/E
-36.84x
P/B
2.47x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$1.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$2M
Beta
0.64
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NIKI Overview
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NIKI's potential to beat the market
- NIKI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NIKI
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $243.47 | A | |
| $11.15 | A | |
| $8.60 | A |
Be the first to know about important NIKI news, forecast changes, insider trades & much more!
NIKI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NIKI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NIKI ($7.00) is overvalued by 516,436.06% relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NIKI ($7.00) is not significantly undervalued (516,436.06%) relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NIKI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NIKI due diligence checks available for Premium users.
Valuation
NIKI fair value
Fair Value of NIKI stock based on Discounted Cash Flow (DCF)
Price
$7.00
Fair Value
$0.00
Overvalued by
516,436.06%
NIKI ($7.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NIKI ($7.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NIKI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NIKI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-36.84x
Industry
21.5x
Market
11.71x
NIKI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.47x
Industry
5.33x
NIKI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NIKI's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
NIKI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.7M
Liabilities
$4.9M
Debt to equity
0.21
NIKI's short-term liabilities ($4.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NIKI's short-term assets ($3.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NIKI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NIKI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NIKI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NIKI vs Biotech Stocks
Niki Biosolutions Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.